Giornale italiano di oncologia最新文献

The aim of our study was to evaluate the usefulness of the tumor markers CA 72.4, CEA and CA 19.9 in the monitoring of gastrointestinal carcinomas. Our experience demonstrated the usefulness of the determination of CA 72.4 in the follow up of patients with gastrointestinal neoplasms.

We made a study on patients suffering from neoplasias treated with cisplatinum to compare antiemetic efficacy of alizapride or associated to dexamethasone. We divided patients in two groups. We somministred alizapride alone to the first group and alizapride plus dexamethasone to the second one. We evaluated presence or absence of emesis, its intensity and eventual tossic effects due to the drugs through an autocompilative questionnaire given to the patients. Our results didn't show important statistical differences between the two groups, though association with dexamethasone gets better emesis control. Alizapride anyway, didn't present important collateral effects, particularly extrapyramidal ones.

The Author analyzes the ranitidine's role in course of antiblastic treatments. The drug, administrated the night orally at the dose of 300 mgr/pro die, improves the tolerance of antineoplastic drugs and determines less incidence of gastric injuries in oncologic patients.

We have retrospectively examined 94 evaluable patients with metastatic osteolysis from breast cancer (BC) and non-small cell lung (NSCLC) cancer, who received RT from Nov. 88 to Nov. 89.27 (15 BC and 12 NSCLC) were in treatment with Clodronate for at least 3 days from the beginning of RT; of the remaining 67 treated with RT alone, 31 had NSCLC and 36 BC. We have evaluated: increase in pain (IP) occurring on the first days of RT, percentages of complete pain relief (CPR) at the end of RT and 4-6 weeks after. A decreased occurrence of IP was observed more in NSCLC patients receiving RT + Clodronate compared to those treated with RT alone (33.3% vs 41.9%). Both at the end of RT and 4-6 weeks after, we registered a significant difference in the percentages of CPR in the RT + Clodronate group (40.7 vs 20.9 and 70.3% vs 53.7%). We believe the points of interest focused in this paper-greater precision in centering and defining the target volume, decreased occurrence of IP during the first days of RT, increase in percentage of CPR--need a prospective confirmation.

The authors exopound three cases of women affected by endometrial carcinoma in which the ascithis has represented the first clinic manifestation in absence of metrorrhage (first two cases); in the third case, instead, the ascithis has appeared four years after the surgical operation of total laparohysterectomy with bilateral annexiectomy and telecobaltotherapy. The association of the malign ascithis with endometrial adenocarcinoma is of rare observation. The Authors think very likely that the intraperitoneal semination in the cases they examined, is due to the infiltration of the myometry, of the regional and iuxtaregional lymphonoids with formation of ascithis.

45 patients with lung cancer at the III and IV stage were treated with once-a-week radiation therapy. Treatments were carried out with a daily fraction, at beginning, of 880 rad (2100 ret) (14 pz.) and 550 rad (1500 ret) afterwards. In both cases the total dose was 4400 rad. All the patients had symptoms of locally advanced cancer: cough (46%), hemoptysis (31%), dyspnea (62%) and chest pain (28%). All of them were out-patients (ECOG 0-1) and presented a Performance Status by Karnofsky of 50-80. The average age was 60 (median 65, range 38-85) with a raised percent (50%) of collateral illness. The selection of once-a-week technique was determined by the bad prognosis and the necessity of symptoms' control, allowing the patients to stay in his proper social and family group. All the time of therapy and the follow-up the values of Performance Status were assigned scrupulously. The analysis showed that the 80% of the patients had a subjective improvement which lasted, on average, 4 months (range 1-21) with an increase of 20 points of Performance Status after the end of therapies. Concluding, the high percentage of success on symptoms presented by the patients, confirms the validity of weekly radiotherapy, which guarantees, besides the palliative effect, the psychological integrity which is necessary in the last period of the life of cancer patient.

Carcinomatous involvement of the pelvic nerves (Pelvic Carcinomatous Neuropathy-PCN-) causes disabling sensorial and motor disturbances of the lower extremities. Recurrent rectal carcinomas are the most common cause of PCN because surgical obliteration of the perirectal fascia. In 31 cases of PCN Authors describe the types of the neoplasm and the sites of involvement of the pelvic nerves evaluating clinical syndromes and Computed Tomography. The results of radiotherapy (doses between 36-56 Gy) in 14 cases of PCN by recurrent rectal cancer are also reported. Although the survival of such patients is poor, radiotherapy has obtained a good palliative result in 50% of them. Personalization of radiation treatment planning is advisable in order to avoid acute side-effects.

15 patients with primary or metastatic pleural effusion were studied: 2 had diagnosis of malignant mesothelioma and 13 of metastatic pleural disease. The treatment used was based on in vitro and in vivo studies which show a synergy between ARA-C and Cisplatin. These drugs were instilled in pleural cavity at the dose of 100 mg./m2 for Cisplatin and 100 mg. for ARA-C. The cavity was drained after 4 hours. The treatment was repeated weekly. All patients had not been previously treated with loco-regional therapy. The response rate was 93% with 10 loco-regional complete remissions (66%). The two patients with malignant mesothelioma achieved a complete remission. The overall toxicity was acceptable. We conclude that combination of Cisplatin and ARA-C is well-tolerated and produces a very high response rate in the treatment of malignant pleural effusions.

Some epidemiological and clinical considerations on 184 cases of multiple myeloma, diagnosed in the period 1970-1989, are reported. The mean annual incidence rate for multiple myeloma was 5.1 per 100,000 residents, with a prevalence in male sex and in patients aged more than 65 years. The most frequent symptoms at presentation were bone pain and anemia, while the main cause of death was renal failure. The survival at three years was about 60%, and at five years about 45%. The subdivision of the patients according to the clinical staging system proposed by Durie and Salmon has demonstrated a significant difference in the three survival curves.